



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Phone : +91 7226995613/14/15 | +91 79 2646 8353, 4002 3839 | Fax : +91 79 26404961

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | ishitadrugs@vsnl.net | URL : www.ishitadrugs.com

Date : 30th June, 2020

To
The Manager
Department of Corporate Services
BSE Limited
Dalal Street, Firoze Jijibhoy Towers,
Mumbai- 400 001, India

Security Code: 524400

Dear Sir/Madam

Subject: Outcome of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we hereby inform you that the Board of Directors of the company at their meeting held on 30th June, 2020, considered and approved, inter-alia, the following:

1. Considered and approved the financial results for the quarter and year ended 31st March, 2020.
2. Considered and approved the appointment of M/s. Meenu Maheshwari & Associates as Secretarial Auditor for the year 2020-21.
3. Considered and approved the appointment of Internal Auditors of the Company for the year 2020-21.
4. Taken on record the Disclosures of Interest of Directors of the Company.
5. Approved the resignation of Ms. Niharika Shah from the post of Company Secretary and Compliance Officer of the Company.
6. Approved the resignation of Mr. Prakash Rastogi as an independent director of the Company.

Kindly take the above on record.

Thanking You.

For, Ishita Drugs and industries Limited

Jagdish Agrawal
Managing Director
DIN : 01031687



"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359

Auditors Report on Annual Financial Results of M/s Ishita Drugs & Industries Ltd. Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

To,
Board Of Directors,
Ishita Drugs & Industries Ltd

We have audited the statement of annual financial result of M/s **Ishita drugs & industries Ltd** for the year ended 31 march, 2020. Attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (listing obligation and Disclosure requirements). Regulations, 2015. These statement is the responsibility of the company's management and has been approved by the boards of directors. This statement has been prepared on the basis of the Generally Accepted Accounting Principles and policies. Our responsibility is to express an opinion on these financial results based on our audit of such annual financial statement. Which have been prepared in accordance with the recognition and measurement principles laid down in accounting standard for interim financial reporting (Ind-AS 34), prescribed, under section 133 of the companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial result are free of material misstatement(S). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best information and according to the explanations given to us these financial result.

- (i) Are presented in accordance with the requirements of regulation 33 of SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015 in this regards and
- (ii) Give a true and fair view of the net profit and other financial information for the period from 01 April, 2019 to 31 March,2020.



Corp. Office : 410-411, Lilamani Corporate Heights, Opp. Ramapir Brts Bus Stand, Nr. Ozone Aangan, New Wadaj, Ahmedabad - 380013, Gujarat
Branch Office : 504, Palladium Business Hub, Above Pantaloons, Opp. 4D Mall - PVR Cinema, Visat Gandhinagar Highway, Ahmedabad-382424

☐ CA Mayank Sancheti +91 8000331632 / 7048685472
Deepak Surana + 91 9429913706
● GSTIN : 24AAOFJ1119R1ZY

✉ camayanksancheti@gmail.com
dpaksurana4u@gmail.com



The financial result include the result for the quarter ended March 31, 2020 being the balancing figure between audited figure in respect of full financial year and the published year to date figures upto the third quarter of the financial year, which were subject to limited review by us.

Date: 29/06/2020

Place: Ahmedabad

For and on Behalf of
JAYMIN SHAH AND ASSOCIATES

Mayank Sancheti

(Partner)



MNo.: 170863

FRN: 129406W

UDIN: 20170863AAAABB1298

ISHITA DRUGS AND INDUSTRIES LIMITED
CIN: L24231GJ1992PLC017054
Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170
Website: www.ishitadrugs.com
Contact: +91 7226995613

Audited Financial Results for the Quarter and Year Ended March 31, 2020

Amount in Lakhs except Per Share data

Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended in the previous Year	Year to date figures for current year ended	Year to date figures for previous year ended
	31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19
	Audited	Un-audited	Audited	Audited	Audited
1 INCOME					
Revenue from Operations	336.51	398.48	295.39	1481.81	908.72
Other Income	5.39	6.93	12.23	17.65	16.34
Total Income	341.90	405.41	307.62	1499.46	925.05
2 EXPENSES					
(a) Cost of Material Consumed	219.17	340.67	215.36	1135.53	620.62
(b) Purchase of Stock-In-Trade	6.35	0.00	6.36	9.25	6.36
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	7.74	(15.96)	7.28	(0.27)	13.16
(d) Employee Benefit Expense	29.36	27.17	28.35	109.80	95.55
(e) Finance Cost	0.56	0.94	3.85	3.47	6.06
(f) Depreciation, Depletion and Amortisation Expense	6.05	3.89	3.62	17.75	15.59
(g) Other Expense	50.96	31.46	28.26	152.59	121.43
Total Other Expenses	50.96	31.46	28.26	152.59	121.43
Total Expenses	320.20	388.16	293.08	1428.11	878.77
3 Total Profit before Exceptional Items and Tax	21.70	17.25	14.54	71.34	46.29
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00
5 Total Profit before Tax	21.70	17.25	14.54	71.34	46.29
6 Tax Expense					
7 Current Tax	5.10	4.89	3.55	17.50	11.50
8 Deferred Tax	(0.87)	0.00	(0.37)	(0.87)	(0.37)
9 Total Tax Expenses	4.23	4.89	3.18	16.63	11.13
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement		0.00	0.00	0.00	0.00
11 Net Profit Loss for the period from continuing operations	17.47	12.37	11.36	54.71	35.16

Jaydip Agrawal



12	Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00
13	Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00
14	Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00
15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00
16	Total Profit / (Loss) for the period	17.47	12.37	11.36	54.71	35.16
17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00
18	Total Comprehensive Income for the Period	17.47	12.37	11.36	54.71	35.16
19	Total profit or loss attributable to					
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00
20	Total comprehensive income for the period attributable to					
	Comprehensive Income for the period attributable to the owners of parents		0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests		0.00	0.00	0.00	0.00
21	Details of Equity Share Capital					
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00
22	Details of Debt Securities					
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00	0.00
25	Earnings Per Share					
(i)	Earnings Per Share for continuing operations					
	Basic Earnings / (Loss) per share from continuing operations	0.58	0.43	0.38	1.83	1.18
	Diluted Earnings / (Loss) per share from continuing operations	0.58	0.43	0.38	1.83	1.18
(ii)	Earnings Per Share for discontinued operations					
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00
(iii)	Earnings per Equity Share					
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.58	0.43	0.38	1.83	1.18
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.58	0.43	0.38	1.83	1.18
26	Debt Equity Ratio	0.00	0.00	0.00	0.00	0.00
27	Debt Service Coverage Ratio	0.00	0.00	0.00	0.00	0.00
28	Interest Service Coverage Ratio	0.00	0.00	0.00	0.00	0.00

Dayanidhi Agrawal



NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on June 30, 2020.
2. Results for the quarter and year ended 31st March, 2020, are in compliance with Indian Accounting Standards ('IndAS') notified by the Ministry of Corporate Affairs.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment. Hence no segment wise figures are published.
4. The figures for the quarter ended 31st March, 2020, are balancing figures between audited figures in respect of full financial year ended 31st March, 2020, and the published year to date figures upto the third quarter ended 31st December, 2019, which have been regrouped / rearranged wherever necessary.
5. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, ISHITA DRUGS AND INDUSTRIES LIMITED




Place Ahmedabad

Date 30-Jun-20

JAGDISH AGRAWAL
MANAGING DIRECTOR

DIN: 01031687

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

Statement of Assets and Liabilities

Amount in ₹

	Particulars	Year Ended	Previous Year Ended
		12 Months Ended	12 Months Ended
		Audited	Audited
		31-03-20	31-03-19
ASSETS			
1	Non-current assets		
	Property, plant and equipment	11369951	12998979
	Capital work-in-progress		
	Investment property		
	Goodwill		
	Other intangible assets		
	Intangible assets under development		
	Biological assets other than bearer plants		
	Investments accounted for using equity method		
	Non-current financial assets	11369951	12998979
	Non-current investments	2068098	1592254
	Trade receivables, non-current		
	Loans, non-current		
	Other non-current financial assets	506200	506200
	Total Non-current financial assets	2574298	2098454
	Deferred tax assets (net)		
	Other non-current assets		
	Total Non-current Assets	13944249	15097433
2	Current assets		
	Inventories	5809314	7387752
	Current financial assets		
	Current investments	50866475	38787641
	Trade receivables, current	13109812	11803412
	Cash and cash equivalents	4017892	3248456
	Bank balance other than cash and cash equivalent	5978175	6862594
	Loans, current	0	10340
	Other current financial assets	284000	168263
	Total current financial assets	74256353	60880706
	Current tax assets (net)		
	Other current assets		
	Total Current Assets	0	0
3	Non-current assets classified as held for sale		
4	Regulatory deferral account debit balances and related deferred tax Assets		
	TOTAL ASSETS	94009916	83365891

Jyoti Agrawal



EQUITIES AND LIABILITIES			
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	29903000	29903000
	Other equity	39707583	34236519
	Total Equity attributable to owners of Parent	69610583	64139519
	Non controlling interest		
	Total Equity	69610583	64139519
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	419487	1224637
	Trade payables, non-current		
	Other non-current financial liabilities		
	Total Non-current financial liabilities	419487	1224637
	Provisions, non-current		
	Deferred tax liabilities (net)	469729	556394
	Deferred government grants, Non-current Other non-current liabilities		
	Total Non-current liabilities	469729	556394
	Current liabilities		
	Current financial liabilities		
	Borrowing, current	1655517	45052
	Trade payables, current	18936050	13785833
	Other current financial liabilities	993862	974234
	Total current financial liabilities	21585429	14805119
	Other current liabilities		
	Provisions, current	1669022	1714600
	Current tax liabilities (Net)	255666	925622
	Deferred government grants, Current		
	Total current liabilities	1924688	2640222
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	Total Liabilities	0	0
	Total Equity and Liabilities	94009916	83365891

For, ISHITA DRUGS AND INDUSTRIES LIMITED

		JAGDISH AGRAWAL
Place	Ahmedabad	MANAGING DIRECTOR
Date	30-Jun-20	DIN: 01031687

Jagdish Agrawal





ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Phone : +91 7226995613/14/15 | +91 79 2646 8353, 4002 3839 | Fax : +91 79 26404961
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.
E-mail : ishitadrugs@gmail.com | ishitadrugs@vsnl.net | URL : www.ishitadrugs.com

Date: 30th June, 2020

To,

The Company Section
The Bombay Stock Exchange
Phiroze Jijibhoy Towers
Dalal Street, Bombay-400 001

Security Code: 524400

Dear Sir,

Sub: Declaration regarding unmodified Audit report in respect of standalone financial statement for the year 2019-20 under SEBI (LODR) Regulations, 2015

We hereby declare that we are hereby submitting the Audit Report in respect of standalone financial statement for the financial year 2019-20 along with financial results on 30th June, 2020. Pursuant to the requirement under 33(3) (d) of SEBI (Listing Obligation and Disclosure requirement) Regulation, 2015 we hereby declare that the auditors have expressed an unmodified opinion in their audit reports on standalone financial statement of the Company for the financial year 2019-20.

Thanking You

For Ishita Drugs and Industries Limited

Authorized Signatory



Jaydevi Agrawal

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054
D & B D-U-N-S Number - 65-018-0359